Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 - TradingView

Reuters | Nov. 12, 2025, 7:37 a.m. | Original
Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 TradingView
US stock futures climb on expectations of end to federal shutdown - Reuters Polestar falls on bigger Q3 loss, reverse stock split - TradingView